Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Aldose reductase inhibitors described by Grelan

July 12, 1996

Optro enters U.S./Canadian phase II trials

July 12, 1996

Pharmacia & Upjohn terminates Hemopure codevelopment agreement

July 12, 1996

Results of fat accumulation/PAI-1 levels relationship study disclosed

July 12, 1996

Aryloxypropanolamine beta3-adrenoceptor agnoists from Bristol-Myers Squibb

July 12, 1996

(+)-Sch-58053: Schering-Plough's cholesterol absorption inhibitor

July 12, 1996

Pfizer and Warner-Lambert sign atorvastatin agreement

July 12, 1996

Cathepsin B and L inhibitors in Fujisawa's pipeline

July 12, 1996

Non-steroidal compounds for postmenopausal disorders described by Lilly

July 12, 1996

Low-estrogen oral contraceptives have low stroke risk

July 5, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM
BioWorld
Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....